Advertisement
Advertisement

DMAC

DMAC logo

DiaMedica Therapeutics Inc. Common Stock

6.73
USD
Sponsored
-0.12
-1.80%
Mar 27, 12:36 UTC -4
Open

DMAC Earnings Reports

Positive Surprise Ratio

DMAC beat 20 of 28 last estimates.

71%

Next Report

Next Week
Date of Next Report
Mar 30, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.18
Implied change from Q-- -- (Revenue/ EPS)
--
/
--
Implied change from Q4 24 (Revenue/ EPS)
--
/
--

DiaMedica Therapeutics Inc. Common Stock earnings per share and revenue

On --, DMAC reported earnings of -- USD per share (EPS) for -- --, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q4 25, 6 analysts forecast an EPS of -0.18 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
logo
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.41
Surprise
+11.29%
logo
Spero Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.20
Actual
$0.53
Surprise
+359.80%
logo
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-2.94%
logo
Alpha Cognition Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.30
Surprise
-8.93%
logo
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
logo
Cognition Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.02
Surprise
+76.47%
logo
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
logo
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-
Actual
-$0.71
Surprise
-
logo
CollPlant Biotechnologies Ltd Ordinary Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.67
Surprise
-245.72%
FAQ
For Q-- --, DiaMedica Therapeutics Inc. Common Stock reported EPS of --, Inline estimates by --, and revenue of --, -- -- expectations.
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
The next earning report is scheduled for Mar 30, 2026.
Based on 6 analysts, DiaMedica Therapeutics Inc. Common Stock is expected to report EPS of -$0.18 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement